Compass Therapeutics, Inc. Common Stock
$1.84
-$0.01 (-0.54%)
$1.81Day Range$1.87
Key Statistics
Market Cap
$333.16M
Shares Outstanding
180.1M
Primary Exchange
XNAS
Currency
USD
Type
CS
IPO Date
Nov 13, 2020
Round Lot
100
Locale
US
Trading Data
Day Open
$1.86
Day High
$1.87
Day Low
$1.81
Volume
1.57M
VWAP
$1.84
Prev Close
$1.85
Transactions
--
Acc. Volume
--
About Compass Therapeutics, Inc. Common Stock
Compass Therapeutics Inc is a clinical-stage oncology-focused biopharmaceutical company that develops proprietary antibody therapeutics to engage the immune system to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth. It is engaged in drug discovery by leveraging its proprietary antibody discovery engine to target the immune system and identify optimal combinations empirically broadly. Through StitchMabs and common light chain platforms, these combinatorial insights can be rapidly translated into tailored bispecifics with monoclonal-like manufacturability. Its pipeline is comprised of the following product candidates; CTX-009, CTX-471, CTX-10726, VEGF-A, Bispecific, and CTX-8371.
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)SIC 283639 employees80 GUEST STREET, BOSTON, MA, 02135617-500-8099IPO Nov 13, 2020US / STOCKSActiveWebsite
Identifiers
- CIK
- 0001738021
- Composite FIGI
- BBG00LPXKF25
- Share Class FIGI
- BBG00LPXKF34
- Ticker Root
- CMPX
- SIC Code
- 2836
About Compass Therapeutics, Inc. Common Stock (CMPX) Stock
Compass Therapeutics, Inc. Common Stock (CMPX) closed the 2026-09-18 session at $1.84, down 0.54% versus the previous close (-0.01). The stock opened at $1.86 and traded between $1.81 and $1.87 during that session. Session trading volume was 1.6M shares. The volume-weighted average price (VWAP) is $1.84.
Compass Therapeutics Inc is a clinical-stage oncology-focused biopharmaceutical company that develops proprietary antibody therapeutics to engage the immune system to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth. It is engaged in drug discovery by leveraging its proprietary antibody discovery engine to target the immune system and identify optimal combinations empirically broadly. Through StitchMabs and common light chain platforms, these combinatorial insights can be rapidly translated into tailored bispecifics with monoclonal-like manufacturability. Its pipeline is comprised of the following product candidates; CTX-009, CTX-471, CTX-10726, VEGF-A, Bispecific, and CTX-8371.
Compass Therapeutics, Inc. Common Stock has a market capitalization of $333.2 million. The company operates in the BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) industry classification. CMPX is listed on the XNAS exchange. The company employs approximately 39 people. Compass Therapeutics, Inc. Common Stock is headquartered in BOSTON, MA. The recorded listing date is 2020-11-13.
On this page you can find market CMPX stock price data, interactive price charts with multiple timeframes (1 day to max history), company financials including income statements, balance sheets, and cash flow statements, technical indicators (SMA 50, SMA 200, EMA 20, MACD, RSI), latest news and sentiment analysis, dividend history, stock splits, short interest data, float information, and related stocks.
Explore more: View today's market movers, use the stock screener, or browse all sectors. See more stocks in the BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) sector.